Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06057402 · ClinicalTrials.gov registry record · Phase 4
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
A Phase 4 study of Multiple Myeloma, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
- 20
- Study locations
NCT06057402: Recruiting Phase 4 study of Multiple Myeloma, sponsored by Pfizer.
NCT06057402 is a Phase 4 study of Multiple Myeloma that is actively recruiting participants, run by Pfizer. The registered enrollment target is 80 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06057402, a Phase 4 study of Multiple Myeloma, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
Conditions Studied
Interventions
- DRUG Elranatamab
Study Locations (20)
Colorado
- UCHealth Poudre Valley Hospital - Fort Collins
- UCHealth Harmony - Fort Collins
- UCHealth Greeley Hospital - Greeley
- Longs Peak Hospital - Longmont
- UCHealth Longs Peak Medical Center - Longmont
- UCHealth - Medical Center of the Rockies - Loveland
Florida
- Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center - Coral Gables
- University of Miami Hospital and Clinics Deerfield Beach - Deerfield Beach
- Sylvester Comprehensive Cancer Center - Miami
- University of Miami Hospital and Clinics - Griffin Cancer Research Building - Miami
- University of Miami Hospital and Clinics - Miami
Victoria
- Epworth Freemasons - Melbourne
- Epworth Hospital - Richmond
- Slade Pharmacy - Richmond
Michigan
- University of Michigan - Ann Arbor
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion) - Detroit
Alberta
- Arthur J.E. Child Comprehensive Cancer Centre - Calgary
- Cross Cancer Institute - Edmonton
Texas
- St. David's South Austin Medical Center - Austin
Quebec
- McGill University Health Centre - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-10-03 |
| Est. Completion | 2032-02-22 |
| Phase | Phase 4 |
What NCT06057402 shows while recruiting
NCT06057402 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which Elranatamab is the first listed.
NCT06057402 names 20 study sites across 7 states, led by Colorado, Florida, Victoria.
Frequently Asked Questions
What is clinical trial NCT06057402 about?
NCT06057402 is a clinical study titled "Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)". This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.
What is the current status of trial NCT06057402?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2023-10-03. Estimated completion is 2032-02-22.
What conditions does trial NCT06057402 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT06057402?
The interventions under investigation include: Elranatamab (DRUG).
Who is sponsoring clinical trial NCT06057402?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06057402 being conducted?
This trial has 20 study locations across Colorado, Florida, Michigan, Texas, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06057402's enrollment target sits among peer trials
80 199th of 438 higher than 238 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
RECRUITING · Phase 4
-
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
RECRUITING · Phase 4
-
A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)
ACTIVE NOT RECRUITING · Phase 4
-
Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma
COMPLETED · Phase 4
-
Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants
COMPLETED · Phase 4
-
Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI